-       Report 
- July 2025
-  175 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- April 2025
-  175 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- March 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- January 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- January 2025
-  175 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
           -       Report 
- May 2025
-  100 Pages 
- Global 
   From       €4249EUR$4,750USD£3,737GBP 
            -       Report 
- April 2025
-  130 Pages 
- Global 
   From       €3687EUR$4,123USD£3,244GBP 
      €4338EUR$4,850USD£3,816GBP 
          -       Report 
- June 2025
-  103 Pages 
- Global 
   From       €3086EUR$3,450USD£2,714GBP 
          -       Report 
- September 2024
- Global 
   From       €4292EUR$4,799USD£3,776GBP 
          -       Report 
- February 2023
-  185 Pages 
- Global 
   From       €1699EUR$1,899USD£1,494GBP 
          -       Report 
- January 2023
-  231 Pages 
- Global 
   From       €4292EUR$4,799USD£3,776GBP 
          -       Report 
- October 2022
-  115 Pages 
- Global 
   From       €2907EUR$3,250USD£2,557GBP 
          -       Report 
- September 2018
-  111 Pages 
- Global 
   From       €4428EUR$4,950USD£3,895GBP 
          -       Report 
- May 2024
-  454 Pages 
- Global 
   From       €4428EUR$4,950USD£3,895GBP 
          -       Report 
- October 2022
-  320 Pages 
- Global 
   From       €3354EUR$3,750USD£2,950GBP 
          -       Report 
- April 2023
-  109 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
          -       Report 
- February 2023
-  150 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
          -       Report 
- September 2023
-  145 Pages 
- Global 
   From       €3980EUR$4,450USD£3,501GBP 
          -       Report 
- September 2024
-  200 Pages 
- Global 
   From       €4427EUR$4,949USD£3,894GBP 
          -       Report 
- June 2024
-  232 Pages 
- Global 
   From       €4468EUR$4,995USD£3,930GBP 
       
      Bioinks are specialized biomaterials designed for use in 3D bioprinting applications, which involve the creation of three-dimensional structures, such as tissues and organs, from cells and biomaterials. These inks must possess proper rheological properties to allow precise deposition, maintain cell viability, and facilitate tissue maturation post-printing. The development of bioinks is an interdisciplinary field that intersects material science, biology, and engineering. Bioinks can be derived from    natural sources, like collagen, gelatin, and alginate, or can be synthetically produced, such as polyethylene glycol (PEG) based hydrogels. They are tailored to replicate the extracellular matrix, providing a supportive environment for cell proliferation and differentiation. Recent advances have aimed at improving the functionality and complexity of bioinks to enable the fabrication of structures that more closely mimic the natural tissue characteristics, through the incorporation of growth factors, signaling molecules and incorporating different cell types.
In the market of bioinks, a variety of companies have emerged, providing products and services for the growing field of tissue engineering and regenerative medicine. Some notable companies specializing in the development and supply of bioinks include CELLINK, Allevi, Regenovo, Bio3D Technologies, 3D Systems, and Organovo. These companies continue to innovate by offering a range of bioink formulations and bioprinting solutions to cater to the research needs and commercial applications in the bioprinting sector. Show Less   Read more